川芎嗪联合益生菌及柳氮磺胺吡啶对溃疡性结肠炎的临床观察  

Clinical Observation of Ligustrazine Combined with Probiotics and Sulfasalazine for Treatment of Patient with Ulcerative Colitis

作　　者：杨怡莎[1] 倪景斌[1] 孙辉[1] 黎文华[1] 陆健[1] 

机构地区：[1]南京医科大学附属无锡市第二人民医院消化科,江苏无锡214001

出　　处：《现代生物医学进展》2015年第35期6965-6968,共4页Progress in Modern Biomedicine

摘　　要：目的：观察川芎嗪联合益生菌和柳氮磺胺吡啶对溃疡性结肠炎（Ulcerative Colitis,UC）的临床效果。方法：2013年8月至2014年8月在我院接受治疗的UC患者116例根据其治疗分为观察组（n=58）和对照组（n=58）：对照组予以柳氮磺胺吡啶肠溶片（1.0 g/次,4次/d）、益生菌（2-4粒/次,2次/d）治疗,观察组增用川芎嗪（1-2片/次,3次/d）治疗,2周后比较疗效、治疗前后的炎症因子,以及药物不良反应。结果：观察组患者的总有效率高于对照组（96.55%vs 84.48%,P〈0.05）;观察组治疗前、后的白细胞介素-4（Interleukin-4,IL-4;6.84±1.23 VS 18.24±2.56 pg/mL）,IL-6（168.90±32.49 VS 16.24±4.23 ng/L）;IL-10（15.17±3.21VS 16.77±2.53 ng/mL）;肿瘤坏死因子-α（Tumor necrosis factor alpha,TNF-α;6.95±7.25 VS 6.81±1.84 ng/L）;与对照组治疗前、后的IL-4（6.77±1.52 VS 15.53±2.75 pg/mL）;IL-6（170.21±25.68 VS 18.17±2.25 ng/L）;IL-10（15.24±2.83 VS 15.86±2.24ng/mL）;TNF-α（17.01±2.53 VS 7.63±2.27 ng/L）相比差异有统计学意义（P〈0.05）。两组间药物不良反应总发生率无统计学意义（13.79%vs 6.90%,P〉0.05）。结论：川芎嗪联合益生菌及柳氮磺胺吡啶三联方案治疗UC有较好的临床的疗效和安全性。Objective： To observe the clinical effect influence of Ligustrazine combined with probiotics and sulfasalazine in the treatment of ulcerative colitis （UC）. Methods： 116 cases of UC patients who received the treatment in our hospital from August 2013 to August 2014 were divided into observation group and control group with treatment. 116 patients, each had 58 cases, control group were treated with sulfasalazine enteric coated tablets（1.0g/times, 4 times/d）, probiotic（2-4 pieces/time, 2 times/d） for treatment, the observation group on the basis of it another given additional treatment with Ligustrazine （1 -2 pieces/time, 3 times/d）, two groups were treated for 2 weeks, compared the efficacy after treatment, before and after the treatment of inflammatory factors, and adverse drug reaction. Results： The total effective rate of the observation group was significantly higher than that in the control group （96.55% vs 84.48%, P〈 0.05）. The observation group before and after treatment of IL-4 was（6.84± 1.23 ）VS（ 18.24± 2.56）pg/mL; IL-6 was（ 168.90± 32.49）VS （ 16.24± 4.23）ng/L; IL-10 was（ 15.17± 3.21）VS（ 16.77± 2.53）ng/mL; TNF-α was（ 16.95± 7.25）VS（6.81± 1.84）ng/L, compared with the control group before and after treatment of IL-4 was （6.77± 1.52 ）VS （ 15.53 ± 2.75 ）pg/mL; IL-6 was （ 170.21 ± 25.68 ）VS （ 18.17 ± 2.25）ng/L; IL-10 was（ 15.24± 2.83）VS（15.86± 2.24）ng/mL; TNF-α was（ 17.01± 2.53）VS（7.63± 2.27）ng/L, the difference had statistically significant （P 〈0.05）. Two groups of total incidence of adverse drug reactions had no statistically significant （ 13.79% vs 6.90%）. Conclusion： Ligustrazine combined with probiotics and sulfasalazine in the treatment of UC has better clinical effect and safety.

关 键 词：川芎嗪 益生菌 柳氮磺胺吡啶 溃疡性结肠炎 疗效 

分 类 号：R574.62[医药卫生—消化系统]